Tuesday, December 03, 2024 3:12:56 PM
MDCX................................https://www.stockscores.com/charts/charts/?ticker=MDCX
Recent MDCX News
- Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention • GlobeNewswire Inc. • 04/06/2026 11:30:00 AM
- Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset • GlobeNewswire Inc. • 04/01/2026 11:30:00 AM
- Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan • GlobeNewswire Inc. • 03/26/2026 11:30:00 AM
- Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update • ACCESS Newswire • 03/25/2026 08:30:00 PM
- Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst • ACCESS Newswire • 03/18/2026 11:30:00 AM
- Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 • GlobeNewswire Inc. • 03/16/2026 11:30:00 AM
- Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum • ACCESS Newswire • 03/10/2026 11:30:00 AM
- Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- Medicus Pharma reports positive Phase 2 results for SkinJect skin cancer therapy • IH Market News • 03/05/2026 03:01:58 PM
- Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort • GlobeNewswire Inc. • 03/05/2026 12:30:00 PM
- Medicus Pharma To Participate in the 38th Annual Roth Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Medicus Pharma on Bloomberg World • ACCESS Newswire • 02/12/2026 12:30:00 PM
- Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk • GlobeNewswire Inc. • 02/10/2026 12:30:00 PM
- Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony • ACCESS Newswire • 01/23/2026 12:30:00 PM
- Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile • GlobeNewswire Inc. • 01/22/2026 12:30:00 PM
- Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 • GlobeNewswire Inc. • 01/20/2026 12:30:00 PM
- Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women • GlobeNewswire Inc. • 01/12/2026 12:30:00 PM
- Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates • GlobeNewswire Inc. • 01/05/2026 12:30:00 PM
- Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform • ACCESS Newswire • 12/22/2025 12:30:00 PM
- Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement • ACCESS Newswire • 12/05/2025 08:20:00 PM
- Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President • ACCESS Newswire • 12/01/2025 01:00:00 PM
- Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President • GlobeNewswire Inc. • 12/01/2025 12:30:00 PM
- Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
